Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab combinations in advanced cancers
NCT02745769Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Primary completion
- Nov 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of ramucirumab and merestinib in colorectal cancer (CRC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Oct 2016; status: completed.
02
Drugs
ramucirumabmerestinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02745769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745769.